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Safety and Efficacy of Belimumab Plus Standard Therapy 
for Up to Thirteen Years in Patients With Systemic Lupus 
Erythematosus
Daniel J. Wallace,1 Ellen M. Ginzler,2  Joan T. Merrill,3 Richard A. Furie,4  William Stohl,5   
W. Winn Chatham,6 Arthur Weinstein,7  James D. McKay,8 W. Joseph McCune,9 Michelle Petri,10  
James Fettiplace,11  David A. Roth,12  Beulah Ji,11  and Amy Heath13
Objective. To investigate the long- term safety and efficacy of intravenous (IV) belimumab plus standard of care 
(SOC) therapy for systemic lupus erythematosus (SLE) in patients with active, autoantibody- positive SLE.
Methods. The study was designed as a multicenter, open- label, continuation study of IV belimumab given every 4 
weeks in conjunction with SOC therapy in patients with SLE who completed a phase II, double- blind study. Adverse 
events (AEs) and laboratory data were monitored from the first belimumab dose (in either study) until 24 weeks after 
the final dose. Efficacy assessments included SLE Responder Index (SRI) and flare index scores (each assessed at 
16- week intervals) and glucocorticoid use (assessed at 4- week intervals).
Results. Of the 476 patients in the parent study, 298 (62.6%) entered the continuation study, of whom 96 
(32.2%) remained in the study. Patients received belimumab for up to 13 years (median duration of exposure 
3,334.0 days [range 260–4,332 days], total belimumab exposure 2,294 patient- years, median number of infusions 
115.5 [range 7–155]). The percentage of patients with AEs each year remained stable or decreased. Normal serum 
IgG levels were maintained in the majority of patients over the study, and the rate of infections remained stable. 
The percentage of patients who achieved an SRI response increased from 32.8% (year 1) to 75.6% of those 
 remaining on treatment at year 12. The glucocorticoid dose was decreased in patients who had been receiving 
>7.5 mg/day at baseline.
Conclusion. This study is the longest to date to assess belimumab treatment in patients with SLE in clinical trials. 
Belimumab was well tolerated with no new safety concerns, and efficacy was maintained in patients who continued 
the study. For patients who initially exhibited a satisfactory response to belimumab, the treatment continues to be 
well tolerated and provides long- term disease control.
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INTRODUCTION
Intravenous (IV) belimumab (10 mg/kg) is approved for 
the treatment of active, autoantibody- positive systemic lupus 
erythematosus (SLE) in more than 60 countries, including the 
US, Japan, and countries in Europe (1–3). A phase II, placebo- 
controlled, dose- ranging trial (GlaxoSmithKline trial no. LBSL02; 
ClinicalTrials.gov identifier NCT00071487) of IV belimumab 
administered in conjunction with standard of care (SOC) therapy 
in 449 patients with active, autoantibody- positive SLE demon-
strated that belimumab was well tolerated through 52 weeks (4). 
This study also informed the design of phase III trials (5,6) and 
the development of the SLE Responder Index (SRI) (7). Two piv-
otal phase III trials further demonstrated the efficacy and safety 
of IV belimumab plus SOC therapy for up to 76 weeks (5,6).
To investigate the long- term safety and efficacy of  belimumab 
plus SOC therapy, a continuation study of LBSL02 was con-
ducted. Previous interim analyses from this study have shown 
that belimumab was well tolerated, and disease control was 
 maintained through 7 years (8,9). Herein we report the final analy-
sis of this study, which is currently the longest SLE therapy study 
mea suring the efficacy and safety of IV belimumab (9), in which 
patients received treatment with belimumab for up to 13 years.
PATIENTS AND METHODS
Study design. The study was designed as a multicenter, 
open- label, continuation study (GlaxoSmithKline study no. 
BEL112626; ClinicalTrials.gov identifier NCT00583362) of IV 
 belimumab administered in conjunction with SOC therapy in 
patients with SLE who had achieved a satisfactory response to 
belimumab in a phase II, double- blind study (for the study design, 
see Supplementary Figure 1, available on the Arthritis & Rheu-
matology web site at http://onlinelibrary.wiley.com/doi/10.1002/
art.40861/abstract) (4). Patients who completed the double- blind 
phase could continue in the open- label, 24- week extension study. 
In the extension, patients who had received placebo switched 
to 10 mg/kg IV belimumab, and those previously receiving 
 belimumab either continued at the same dose (1, 4, or 10 mg/kg) 
or switched to 10 mg/kg, based on their response at the end of 
the double- blind phase.
Patients who completed the extension study, who had an 
improvement in score on the physician’s global assessment 
(PhGA) of disease activity compared with baseline (prior to the 
first dose of belimumab), and who did not develop a severe 
flare (according to the Safety of Estrogens in Lupus Erythe-
matosus National Assessment [SELENA] version of the SLE 
Disease Activity Index [SLEDAI] Flare Index [SFI] [10]) in the 
last 30 days of the extension study were eligible to enter the 
continuation study. The protocol for the continuation study has 
been reported previously (8,9). Briefly, all patients received 10 
mg/kg IV belimumab every 4 weeks until they withdrew from 
the study or the criteria for ending the study were met (which-
ever came first, 10 years from the enrollment of the last patient 
or ≤100 patients participating in the study). To prevent unnec-
essary long- term exposure to belimumab for patients who 
did not benefit from treatment, stopping rules were applied 
(a complete list of the stopping rules is shown in Supplemen-
tary Table 1, available on the Arthritis & Rheumatology web 
site at http://onlinelibrary.wiley.com/doi/10.1002/art.40861/
abstract). Following withdrawal from the study, patients were 
monitored for an additional 24 weeks.
Institutional review board or ethics committee approval was 
obtained for all study sites. All patients gave their informed con-
sent before entering the long- term continuation study (8,9).
Assessments. Safety was monitored from the first dose of 
study treatment until 24 weeks after the final dose, with adverse 
events (AEs) and laboratory data recorded. Clinical laboratory tests 
included hematology, chemistry, routine urinalysis, measurement 
of serum immunoglobulins (IgG, IgA, IgE, and IgM), and antidrug 
antibody testing. These tests were performed every 8 weeks.
Efficacy assessments were conducted periodically and 
included the following: percentage of patients with an SRI response 
(i.e., achievement of the SRI- 4 criteria) (7) (at 16- week intervals), 
disease activity scores on the SELENA- SLEDAI (10) and the Brit-
ish Isles Lupus Assessment Group (BILAG) Index (11) (at 16-week 
intervals), the PhGA (at 8- week intervals), SFI scores of disease 
flare and severe disease flare (at 16- week intervals), change in 
glucocorticoid use (at 4- week intervals), and serologic measure-
ments (including serum levels of complements C3 and C4 and 
autoantibodies) (at 16- week intervals). Glucocorticoid doses are 
reported in prednisone equivalent units. Low disease activity was 
defined as a SELENA- SLEDAI score of ≤2 and a prednisone dose 
of ≤5 mg/day.
Statistical analysis. All data analyses were conducted 
in the modified intent- to- treat population, defined as all patients 
who received at least 1 dose of belimumab in the continuation 
study. No formal statistical hypothesis testing was performed, 
and all analyses were exploratory. All analyses were performed 
using descriptive statistics. Post hoc analyses included AE rates 
(per 100 patient- years) by preferred term, last observation car-
ried forward (LOCF) for SRI response rates among patients who 
withdrew from the study, categorical analyses of SELENA- SLEDAI 
and PhGA disease activity scores, the cumulative time that the 
patients’ prednisone dose was ≤7.5 mg/day, the number of 
patients with low disease activity at each study visit, and determi-
nation of normalization of anti–double- stranded DNA (anti- dsDNA) 
antibody and C3/C4 complement levels.
Baseline data were recorded prior to the first dose of 
 belimumab (in either the parent study or extension study for those 
who previously received placebo). Data analyses were performed 
using SAS software, version 9.4 (SAS Institute).
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RESULTS
Study population and disposition of the patients. 
Patients with SLE (n = 476) were randomized in the parent study 
to receive IV belimumab or placebo, which was added to SOC 
therapy. Of these, 298 patients (62.6%) entered the continuation 
study, of whom 96 (32.2%) remained in the study to the end 
(year 13) (Figure 1A) and 88 (29.7%) remained in the study for 
≥11 years. Total belimumab exposure was 2,294 patient- years. 
The median duration of exposure was 3,334.0 days (range 260–
4,332 days), and the median number of infusions was 115.5 
(range 7–155). Patient self- withdrawal was the most common 
form of withdrawal (Figures 1A and B); the most frequent rea-
sons for this were a desire to become pregnant, and difficulties 
attending the clinic due to location, travel, or time constraints. 
Withdrawal due to lack of efficacy seldom occurred throughout 
the study, with the frequency of withdrawal because of ineffi-
Figure 1. A, Disposition of the patients with systemic lupus erythematosus randomized to receive placebo or belimumab. B, Frequency and 
reasons for withdrawals per study year. Values are the total number (%) of patients who withdrew, based on the number of patients starting 
each study year. mITT = modified intent- to- treat.
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cacy reaching a maximum of 6 patients in year 3. At years 5, 7, 
and 10, the percentages of patients remaining in the study were 
70.1%, 60.1%, and 44.3%, respectively.
Baseline demographics and disease characteristics of the 
patients have been reported previously (8,9). The majority of 
patients were female (93.2%), and the mean ± SD age was 43.0 
± 11.58 years (Table 1). At baseline, the mean ± SD duration 
of SLE was 9.1 ± 7.8 years, the mean ± SD SELENA- SLEDAI 
score was 8.4 ± 4.68. With regard to adjunct therapies, 31.1% 
of patients were receiving >7.5 mg/day prednisone, and 35.5% 
were not receiving glucocorticoids. Among the study patients, 
81.3% were antinuclear antibody positive.
Safety. Adverse events. The percentage of patients reporting 
AEs each year remained stable or decreased throughout the study 
(Table 2; see also Supplementary Table 2 at http://onlinelibrary.wiley.
com/doi/10.1002/art.40861/abstract). The most frequent AEs (≥15.0 
per 100 patient- years) were arthralgia (29.3 per 100 patient- years), 
upper respiratory tract infection (29.0 per 100 patient- years), sinus-
itis (16.9 per 100 patient- years), urinary tract infection (16.2 per 100 
patient- years), and headache (15.0 per 100 patient- years). The rates 
of the most frequent AEs were stable or declined overall from years 1 
to 11 and onward to the study end (see results in Supplementary Table 
3 at http://onlinelibrary.wiley.com/doi/10.1002/art.40861/abstract). 
The most common serious AEs (≥0.5 events per 100 patient- years) 
were pneumonia (0.9 per 100 patient- years), osteoarthritis (deemed a 
serious AE because of the need for hospitalization for elective surgical 
management; 0.8 per 100 patient- years), noncardiac chest pain (0.7 
per 100 patient- years), pyrexia (0.6 per 100 patient- years), cellulitis, 
chronic obstructive pulmonary disease, abdominal pain, viral gastro-
enteritis, and vomiting (each 0.5 per 100 patient- years).
Forty- four patients (14.9%) discontinued treatment with 
belimumab or withdrew from the study because of an AE. The 
AEs that resulted in discontinuation or withdrawal of more than 1 
patient were invasive ductal breast carcinoma (3 patients [1.0%]) 
and hypogammaglobulinemia (2 patients [0.7%]).
The rate of serious infections and infestations remained 
steady from year 1 (3.7 per 100 patient- years) through year 11 
(6.7 per 100 patient- years) (Table  2). The rate of infections of 
special interest was also stable throughout the study (5.1 per 
100 patient- years) (Table 2). The rate of malignant neoplasms, 
excluding nonmelanoma skin cancer, was 0.6 per 100 patient- 
years; no events were reported in years 1, 2, 8, and 11 and 
beyond year 11; the rate of malignant neoplasms was highest 
in year 10 (2.1 per 100 patient- years). There were no cases of 
progressive multifocal leukoencephalopathy (PML) in this study.
The rate of depression was 9.8 per 100 patient- years (237 
events). Six events of suicide/self- injury occurred (0.2 per 100 
patient- years), 4 of which were serious, with 1 resulting in death. 
There were 7 deaths in the study, and 1 during the follow- up 
period. Causes of death were pneumonia (2 patients [1 due 
to an opportunistic infection]), cardiac arrest, coronary artery 
 disease, acute respiratory distress syndrome, respiratory failure, 
retroperitoneal hemorrhage, and suicide.
Clinical and laboratory parameters. Of the hematology pa-
rameters investigated (activated partial thromboplastin time, 
hemoglobin, neutrophil count, platelet count, and prothrombin 
time), the only parameter for which ≥10% of patients had a 
Table  1. Baseline (prior to the first dose of belimumab) 
demographic and clinical characteristics of the 296 patients in the 
study population*
Female, no. (%) 276 (93.2)
Age, mean ± SD years 43.0 ± 11.58
Ethnicity, no. (%)
Hispanic or Latino 54 (18.2)
Not Hispanic or Latino 242 (81.8)
Race, no. (%)
White 215 (72.6)
Black or African American 68 (23.0)
Other 13 (4.4)
Disease duration, mean ± SD years 9.1 ± 7.80
SELENA- SLEDAI
Mean ± SD score 8.4 ± 4.68
Score ≤9, no. (%) 190 (64.2)
Score ≥10, no. (%) 106 (35.8)
BILAG score at least 1A or 2B, no. (%) 168 (56.8)
PhGA score, mean ± SD 1.30 ± 0.571
SFI flare, no. (%)†
Flare score of at least 1 47 (15.9)
Severe flare score of at least 1 9 (3.0)
Glucocorticoids, no. (%)
None 105 (35.5)
≤7.5 mg/day prednisone equivalent dose 99 (33.4)
>7.5 mg/day prednisone equivalent dose 92 (31.1)
Low C3 and/or low C4 serum levels, no. 
(%)‡
135 (46.1)
Anti- dsDNA antibody positive, no. (%)§ 149 (50.3)
ANA titer, no. (%)¶
≥80 208 (81.3)
<80 48 (18.8)
* BILAG = British Isles Lupus Assessment Group (index of disease 
activity); PhGA = physician’s global assessment (of disease activity). 
† For the Safety of Estrogens in Lupus Erythematosus National As-
sessment version of the Systemic Lupus Erythematosus Disease 
Activity Index (SELENA- SLEDAI) Flare Index (SFI), patients who re-
ceived belimumab in the double- blind phase, any time prior to 
study entry, and patients who received placebo in the double- blind 
phase, between the last visit in the double- blind phase and first 
dose of belimumab in the open- label phase, were assessed. 
‡ Low C3 was defined as <90 mg/dl. Low C4 was defined as <16 mg/
dl. Data were available for 293 patients. 
§ Positivity for anti–double- stranded DNA (anti- dsDNA) antibodies 
was defined as serum levels of ≥30 IU/ml. 
¶ Data for antinuclear antibody (ANA) titers were available for 256 
patients. 
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grade 3 (severe) or grade 4 (potentially life- threatening) value was 
a low neutrophil count (grade 3 in 15.2% of patients [45 of 296] 
and grade 4 in 2.7% of patients [8 of 296]). Gamma- glutamyl 
transferase was the only chemistry measurement in which >5% 
of patients experienced a grade 3 or grade 4 value (grade 3 in 
5.7% of patients [17 of 296] and grade 4 in 3.0% of patients 
[9 of 296]) (complete results for these parameters are shown 
in Supplementary Table 4, available at http://onlinelibrary.wiley.
com/doi/10.1002/art.40861/abstract). With the exception of the 
protein excretion rate (18 [6.1%] of 296 patients with grade 3 or 
4), fewer than 5% of patients had grade 3 or grade 4 abnormali-
ties in any of the urinalysis components (data not shown).
The percentage of patients with serum levels of IgM, IgG, 
and IgA below the lower limit of normal (LLN) increased during 
the study (Figure 2A). There were 57.4% (170 of 296 patients), 
16.2% (48 of 296 patients), and 13.5% (40 of 296 patients) who 
had IgM, IgG, and IgA levels below the LLN, respectively, at 
more than one visit. No serum IgE levels were below the LLN. 
The majority of patients (65.9% [195 of 296]) had normal serum 
IgG levels throughout the study; 4.1% (12 patients) had grade 
3 IgG values (250–399 mg/dl), and 2.4% (7 patients) had grade 
4 IgG values (<250 mg/dl) (see Supplementary Table 4). Of the 
19 patients who had grade 3 or grade 4 serum IgG values, 17 
(5.7%) had at least a 2- grade shift from baseline.
Although there was a reduction in serum IgG levels during 
the study, the rate of infections (serious and nonserious) remained 
stable over time (Table 2). A post hoc analysis showed that 4 of 19 
patients with grade 3 or grade 4 IgG abnormalities had a severe 
and/or serious infection (viral gastroenteritis, urinary tract infection 
and sepsis, bronchitis, cellulitis) ≤28 days before experiencing the 
grade 3 or grade 4 reduction in serum IgG levels.
Efficacy. As the number of participants declined, the per-
centage of patients who achieved an SRI response increased 
from 32.8% (88 of 268) at year 1, week 16 to 75.6% (68 of 90) 
at year 12, week 32 (Figure 3A). Among patients who withdrew 
from the study and had a SELENA- SLEDAI score of ≥4 at base-
line, 59.8% (110 of 184) were SRI responders (LOCF) at the time 
of withdrawal. The percentage of patients with a ≥4- point reduc-
tion from baseline in the SELENA- SLEDAI score also increased, 
from 33.7% (99 of 294) at year 1, week 16 to 76.7% (69 of 90) 
at year 12, week 32. The percentage of patients achieving a 
SELENA- SLEDAI score of ≤2 increased throughout the study, 
from 8.4% (25 of 296) at baseline to 62.2% (46 of 74) at year 12, 
week 48 (Figure 3B).
The percentage of patients with no new BILAG A organ 
domain score and no more than 1 new BILAG B organ domain 
score compared with baseline increased over time, ranging from 
Figure 2. Changes in biomarkers. A, Percentage of patients with serum immunoglobulin levels below the lower limit of normal, by study 
year. For patients with >1 value reported within a year, the last response within the year is summarized. B, Percentage change from baseline in 
anti–double- stranded DNA autoantibody levels among patients who were positive at baseline. C, Percentage change from baseline in serum C3 
levels among patients who had low C3 (<90 mg/dl) at baseline. D, Percentage change from baseline in serum C4 levels among patients who 
had low C4 (<16 mg/dl) at baseline. W = week; Y = year.
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65.9% (195 of 296) during year 1 to 94.3% (83 of 88) at study 
end (Figure 3C). The percentage of patients with low PhGA dis-
ease activity scores (scores of 0 or 1) increased during the study; 
at all time points, only a few patients had PhGA disease activity 
scores higher than 2.5 (Figure 3D).
Rates of SFI flares and severe SFI flares were 1.1 per 
patient- year and 0.1 per patient- year, respectively. The occur-
rence of flares was highest in year 1 and was consistently low 
throughout the study (Figure 4A).
At baseline, 190 patients (64.5%) were receiving glucocorti-
coids; of these, 25 (13.2%) discontinued glucocorticoids for the 
remainder of the study. The median percentage change from 
baseline in daily prednisone dose was greatest at year 13, week 
24 (88% [range −100 to 33.33%]; n = 16) (Figure  4B). Of the 
patients receiving >7.5 mg/day prednisone at baseline, the per-
centage achieving a dose of ≤7.5 mg/day increased over time 
(Figure 4C) to a maximum of 53.8% (14 of 26 patients) at year 12, 
week 48. Of the 99 of 296 patients receiving ≤7.5 mg/day pred-
nisone at baseline, 23 (23.2%) maintained a dose of ≤7.5 mg/day 
throughout the study. The percentage of patients who had an 
increase in prednisone dose to >7.5 mg/day increased from year 
1, week 8 (3.0% [6 of 200 patients]) to a maximum of 20.4% (11 
of 54 patients) at year 12, week 40 (Figure 4C; see also Supple-
mentary Figure 2 at http://onlinelibrary.wiley.com/doi/10.1002/
art.40861/abstract).
The percentage of patients achieving low disease activity (a 
SELENA- SLEDAI score of ≤2 and prednisone dose ≤5 mg/day) 
increased throughout the study, from 13.9% (41 of 294 patients) 
at year 1, week 16 to a maximum of 57.1% (4 of 7 patients) at year 
13, week 32 (Figure 4D).
Disease activity following withdrawal from the 
study. Following withdrawal from the study, there was little 
change in disease activity at follow- up weeks 8 and 24 (see results 
in Supplementary Table 5, available at http://onlinelibrary.wiley.
com/doi/10.1002/art.40861/abstract). The percentage of patients 
who achieved an SRI response increased slightly from follow- up 
week 8 (61.9% [122 of 197 patients]) to follow- up week 24 (64.0% 
[114 of 178 patients]). However, the percentage of patients who 
developed an SFI flare (week 8, 20.5% [45 of 219 patients]; week 
Figure 3. Treatment response measures and percentage of assessed patients with treatment response, according to achievement of the 
Systemic Lupus Erythematosus (SLE) Responder Index criteria (A), 4 categories of disease activity scores on the Safety of Estrogens in Lupus 
Erythematosus National Assessment (SELENA) version of the SLE Disease Activity Index (SLEDAI) (B), no new British Isles Lupus Assessment 
Group (BILAG) A organ domain score and no more than 1 new BILAG B organ domain score from baseline (C), and 3 categories of scores on 
the physician’s global assessment (PhGA) of disease activity (D). Numbers of patients in A, B, and D are from the final time point of each year. 
W = week; Y = year.
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24, 21.1% [42 of 199 patients]) or a severe SFI flare (week 8, 2.7% 
[6 of 219 patients]; week 24, 3.0% [6 of 199 patients]) remained 
stable between the follow- up time points.
Biomarkers. Anti- dsDNA autoantibody levels decreased in 
the serum of patients who were considered anti- dsDNA positive 
at baseline (Figure 2B), and of the 152 patients with levels above 
the upper limit of normal at baseline, the anti- dsDNA antibody 
 levels returned to normal in 23 patients (15.1%) and remained nor-
mal during the study. Complement levels increased in the serum 
of patients who had low levels at baseline (Figures 2C and D). Of 
the 88 patients with low serum C3 levels and the 116 patients with 
low serum C4 levels at baseline, the levels normalized in 7 patients 
(8.0%) and 14 patients (12.1%), respectively, and remained nor-
mal during the study.
DISCUSSION
This study provides up to 13 years of data on the safety 
and efficacy of belimumab plus SOC therapy for the treatment 
of SLE. That approximately one- third of patients continued to 
receive belimumab for at least 10 years is extraordinary, particu-
larly in light of the rates of adherence to other medications used 
for and studied in SLE (12). Few patients withdrew due to a lack 
of efficacy, and the long- term safety profile of belimumab was 
acceptable.
The rates and nature of AEs were consistent with the known 
safety profile of belimumab (4–6,8,9,13,14), and there was no 
increase in AEs over time. The rate of self- injury/suicide remained 
low throughout this study and was similar to that reported for the 
open- label extension of the phase III studies, which investigated 
the safety of belimumab for up to 6 years in nearly 1,000 patients 
(13). The incidence of death was 2.7% (0.3 per 100 patient- years); 
this compares with a mortality rate of 1.1% reported until year 6 
in the continuation of the phase III studies (13). Other SLE studies 
have reported higher rates of mortality than this study; for exam-
ple, a multinational study of 9,547 patients with an average fol-
low- up of 8.1 years reported a 13.1% incidence of death (15), 
and a study in the US estimated a 10- year mortality rate of 26% 
in patients with SLE compared with 19% in matched controls 
(16). The relatively low incidence of death in the present study is 
likely related to the exclusion of patients with active lupus nephri-
tis or central nervous system disease (4), but the steroid- sparing 
effect and/or lower rate of organ damage accrual associated with 
 belimumab might also be a contributing factor (13,14,17).
Consistent with the findings from previous studies (14), there 
was an increase in the percentage of patients with low serum IgG 
levels; however, the incidence of infections remained stable.
Figure 4. A, Rates of all flares and severe flares according to the Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA) 
version of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) Flare Index (SFI). B, Median percentage change in prednisone 
dose from baseline. C, Percentage of patients with a prednisone dose increase from ≤7.5 mg/day or a reduction from >7.5 mg/day. D, Percentage 
of patients with low disease activity, defined as a SELENA- SLEDAI score ≤2 and prednisone dose ≤5 mg/day. pt- y = patient- years; W = week; 
Y = year.
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Sporadic cases of PML have been reported in patients 
with SLE (18), but rarely in those receiving belimumab (19). In 
this study, there were no reported cases of PML; however, the 
study was not powered to assess PML incidence. Although it is 
likely that all immunosuppressants increase the risk of PML in 
patients with SLE (20), this seems to remain a rare event, and 
there is currently no evidence to suggest that belimumab further 
increases the risk.
As patient withdrawals occurred over time, there was an 
increase in the percentage of patients who achieved an SRI 
response. Although it is unlikely that patients with active disease 
might respond better to belimumab after a year or more of not 
responding to treatment, another way to examine response rates 
is to consider the risk of flare in patients who may have already 
responded. The rates of all SFI flares and severe SFI flares were 
highest in the first year of the study; from year 5, the flare rates 
were consistently low, indicating that patients who benefit from 
belimumab can maintain stable disease. Throughout the study, 
those patients remaining had reduced requirements for gluco-
corticoids, and the percentage achieving low disease activity 
increased. Furthermore, patients continued to have serologic 
improvements. These findings support the likelihood of sus-
tained, long- term efficacy of belimumab in patients who respond 
to treatment.
During the 24- week follow- up period after study discontin-
uation, disease activity remained stable, with little change in the 
percentages of the population who achieved an SRI response, 
experienced SFI flares, or had changes in prednisone dose. 
Longer- term studies with controls are required to fully investigate 
the effects of discontinuing belimumab, because many factors 
may affect this, including duration of belimumab exposure, dis-
ease severity at discontinuation, possible selection bias in those 
who returned for follow- up visits, and changes in SOC.
This study had several limitations. Because it was an 
open- label study with no placebo- controlled arm, and the 
SOC therapies varied, no treatment comparison can be made. 
Therefore, the results cannot be unequivocally attributed to 
belimumab.
In the double- blind phase of the study, some patients ini-
tially received lower doses of belimumab before switching to 
the licensed 10 mg/kg dose. In this analysis, the doses were 
pooled, given that there were no significant differences observed 
in the AE profile between the 3 doses in phase II (4). Patients 
had 1 year of acceptable response to treatment with placebo 
or belimumab plus SOC therapy before beginning open- label 
treatment with belimumab; this resulted in patients having 
more stable disease at the time of entering into the continua-
tion study. Baseline for all patients was the assessment prior to 
the first dose of belimumab; therefore, the first year reported for 
this study was double- blind exposure for patients randomized 
to receive belimumab, and open- label exposure for patients 
randomized to receive placebo. Not surprisingly, patients who 
received placebo in the double- blind phase and still qualified as 
stable enough to continue had lower baseline disease activity 
compared with patients who received belimumab throughout 
(data not shown).
Patients who remained in the study were likely to be 
those who responded better or tolerated belimumab better 
than patients who withdrew; hence, the findings may not be 
representative of all patients with SLE. However, the popula-
tion who entered the continuation study had similar baseline 
demographics as that in the double- blind study population 
(4,9). For the large percentage of patients who remained in the 
study (70.1% at 5 years, 60.1% at 7 years, and 44.3% at 10 
years), the results suggest that patients who initially respond 
to belimumab and continue to receive treatment are likely to 
experience long- term benefits with continued or improved dis-
ease control.
In conclusion, this study describes the long- term safety 
and efficacy of belimumab in patients with SLE. It is the longest 
study of belimumab to date, with a high percentage of patients 
receiving treatment for >10 years. This study provides further 
safety and efficacy data that are consistent with the data from 
the phase III long- term extension studies. It will be important to 
investigate the effects of stopping belimumab in patients who 
have achieved stable, long- term low- level disease activity; a 
study (ClinicalTrials.gov identifier NCT02119156) is under way 
to investigate this question.
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